Literature DB >> 7584868

Urinary biochemical markers for bone resorption during the menstrual cycle.

I Gorai1, O Chaki, M Nakayama, H Minaguchi.   

Abstract

In order to analyze the effects of serum ovarian steroid hormones on bone metabolism during the menstrual cycle, we have measured urinary levels of type I collagen cross-linked N-telopeptide (NTx), hydroxylysylpyridinoline (HP), lysylpyridinoline (LP). and hydroxyproline (OH-Pr) in nine healthy Japanese women, aged 22-43 years, with normal ovarian function. The cycles were synchronized by serum LH peaks, and follicular and luteal periods were normalized by lengths. Serum gonadotropins and ovarian sex steroids showed significantly different cyclic variations during the menstrual periods. Urinary NTx remained unchanged during the early follicular period, showed a rise during the mid- and late follicular period, and a fall during the mid- and late luteal periods. There were significant differences in NTx levels between early follicular period and midfollicular period (P < 0.01), or late follicular period (P < 0.05), and between early luteal period and late luteal period (P < 0.05). The levels of HP and LP showed a rise during the early an midfollicular periods and a fall during the midluteal period. The correlation of NTx with urinary OH-Pr was better than with urinary HP or LP (r = 0.731 versus r = 0.449 or r = 0.634). This variation suggests that cyclic changes in serum ovarian sex steroids might modulate bone resorption markers during the menstrual cycle.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7584868     DOI: 10.1007/BF00298428

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  37 in total

1.  Osteoclasts isolated from membranous bone in children exhibit nuclear estrogen and progesterone receptors.

Authors:  J M Pensler; J A Radosevich; R Higbee; C B Langman
Journal:  J Bone Miner Res       Date:  1990-08       Impact factor: 6.741

2.  Calcium-regulating hormones across the menstrual cycle.

Authors:  K N Muse; S C Manolagas; L J Deftos; N Alexander; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1986-06       Impact factor: 5.958

3.  Changes in biochemical markers of osteoblastic activity during the menstrual cycle.

Authors:  H K Nielsen; K Brixen; R Bouillon; L Mosekilde
Journal:  J Clin Endocrinol Metab       Date:  1990-05       Impact factor: 5.958

4.  Estrogen binding, receptor mRNA, and biologic response in osteoblast-like osteosarcoma cells.

Authors:  B S Komm; C M Terpening; D J Benz; K A Graeme; A Gallegos; M Korc; G L Greene; B W O'Malley; M R Haussler
Journal:  Science       Date:  1988-07-01       Impact factor: 47.728

5.  Alkaline-phosphatase activity during menstruation.

Authors:  L J DeMerre; F S Litofsky
Journal:  Fertil Steril       Date:  1968 Jul-Aug       Impact factor: 7.329

6.  Possible variation in bone resorption during the normal menstrual cycle.

Authors:  A Schlemmer; C Hassager; J Risteli; L Risteli; S B Jensen; C Christiansen
Journal:  Acta Endocrinol (Copenh)       Date:  1993-11

7.  The short-term effects of conjugated estrogen on bone turnover in older women.

Authors:  K M Prestwood; C C Pilbeam; J A Burleson; F N Woodiel; P D Delmas; L J Deftos; L G Raisz
Journal:  J Clin Endocrinol Metab       Date:  1994-08       Impact factor: 5.958

8.  Increased sensitivity of bone to parathyroid hormone in ovariectomized rats.

Authors:  H Orimo; T Fujita; M Yoshikawa
Journal:  Endocrinology       Date:  1972-03       Impact factor: 4.736

9.  Structure of a cDNA for the pro alpha 2 chain of human type I procollagen. Comparison with chick cDNA for pro alpha 2(I) identifies structurally conserved features of the protein and the gene.

Authors:  M P Bernard; J C Myers; M L Chu; F Ramirez; E F Eikenberry; D J Prockop
Journal:  Biochemistry       Date:  1983-03-01       Impact factor: 3.162

10.  Unchanged biochemical indices of bone turnover despite fluctuations in 1,25-dihydroxyvitamin D during the menstrual cycle.

Authors:  L Tjellesen; C Christiansen; L Hummer; N E Larsen
Journal:  Acta Endocrinol (Copenh)       Date:  1983-03
View more
  8 in total

1.  Age-related changes in bone biochemical markers and their relationship with bone mineral density in normal Chinese women.

Authors:  Yin-Zhen Pi; Xian-Ping Wu; Shi-Ping Liu; Xiang-Hang Luo; Xing-Zhi Cao; Hui Xie; Er-Yuan Liao
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

2.  Biochemical markers of bone turnover: part I: biochemistry and variability.

Authors:  Markus J Seibel
Journal:  Clin Biochem Rev       Date:  2005-11

3.  Changes of serum sclerostin and Dickkopf-1 levels during the menstrual cycle. A pilot study.

Authors:  Chrysoula G Liakou; George Mastorakos; Konstantinos Makris; Ioannis G Fatouros; Alexandra Avloniti; Helen Marketos; Julia D Antoniou; Antonios Galanos; Ismene Dontas; Demetrios Rizos; Symeon Tournis
Journal:  Endocrine       Date:  2016-09-06       Impact factor: 3.633

4.  Alfacalcidol-supplemented raloxifene therapy has greater bone-sparing effect than raloxifene-alone therapy in postmenopausal Japanese women with osteoporosis or osteopenia.

Authors:  Itsuo Gorai; Shin Hattori; Yaku Tanaka; Yasuhisa Iwaoki
Journal:  J Bone Miner Metab       Date:  2011-12-02       Impact factor: 2.626

Review 5.  Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease.

Authors:  Matthew B Greenblatt; Joy N Tsai; Marc N Wein
Journal:  Clin Chem       Date:  2016-12-09       Impact factor: 8.327

6.  Assessment of adherence to treatment of postmenopausal osteoporosis with raloxifene and/or alfacalcidol in postmenopausal Japanese women.

Authors:  Itsuo Gorai; Yaku Tanaka; Shin Hattori; Yasuhisa Iwaoki
Journal:  J Bone Miner Metab       Date:  2009-08-06       Impact factor: 2.626

7.  Poor glycemic control is associated with low BMD detected in premenopausal women with type 1 diabetes.

Authors:  K K Danielson; M E Elliott; T LeCaire; N Binkley; M Palta
Journal:  Osteoporos Int       Date:  2008-10-02       Impact factor: 4.507

8.  Short-term prolactin administration causes expressible galactorrhea but does not affect bone turnover: pilot data for a new lactation agent.

Authors:  Gabrielle Page-Wilson; Patricia C Smith; Corrine K Welt
Journal:  Int Breastfeed J       Date:  2007-07-24       Impact factor: 3.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.